Compare Pfizer Inc (PFE) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Wynn Resorts, Limited — how do they compare? Pfizer Inc trades at $24.9 (market cap $142.14B), while Wynn Resorts, Limited trades at $93.92 (market cap $9.82B). The key difference: Pfizer Inc is far larger — about 14.5× Wynn Resorts, Limited's market cap, and Pfizer Inc pays the higher dividend (6.9%). Which is the better fit depends on your goals.
| PFE | WYNN | |
|---|---|---|
Market Cap | $142.14B | $9.82B |
Volume | 29,869,932 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $28.56 | $133.34 |
52-Week Low | $23.29 | $94.63 |
Enterprise Value | $192.80B | $20.19B |
Dividend Yield | 6.9% | 1.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.
Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.
Wynn Resorts (WYNN) trades at $94.63, down 2.08% today, amid a bearish technical signal with recent earnings misses. The company maintains strong revenue growth with $7.14B in 2025, though net margins have compressed to 4.58%. Recent news highlights operational awards and Q2 2026 earnings anticipation. Technical indicators show support near $93-$95 with resistance at $97-$99, while RSI levels suggest neutral momentum.
Outlook remains mixed: analyst consensus is bullish with a $135.50 price target (64% buy ratings), but high debt ($10.5B long-term) and margin pressure pose risks. The stock offers potential upside if Macau and Las Vegas momentum sustains, though geopolitical and competitive headwinds require monitoring. Near-term catalysts include Q2 earnings on August 4, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
